HOTCHKIS & WILEY's HALO Position Overview
HOTCHKIS & WILEY (via Hotchkis & Wiley Capital Management LLC) currently holds 141,148 shares of Halozyme Therapeutics, Inc. (HALO) worth $9.5 M, representing 0.03% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, HOTCHKIS & WILEY has initiated a new position in HALO, representing a fresh investment thesis on this company. Largest addition occurred in Q4 2025, adding 6,518 shares.
Analysis based on 13F filings available since 2013 Q2
HOTCHKIS & WILEY's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by HOTCHKIS & WILEY
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +6,518 | Add 4.84% | 141,148 | $67.30 |
| Q3 2025 | +134,630 | New Buy | 134,630 | $73.34 |
HOTCHKIS & WILEY's Halozyme Therapeutics Investment FAQs
HOTCHKIS & WILEY first purchased Halozyme Therapeutics, Inc. (HALO) in Q3 2025, acquiring 134,630 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
HOTCHKIS & WILEY has held Halozyme Therapeutics, Inc. (HALO) for 2 quarters since Q3 2025.
HOTCHKIS & WILEY's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q3 2025, adding 134,630 shares worth $9.87 M.
According to the latest 13F filing for Q4 2025, HOTCHKIS & WILEY's firm, Hotchkis & Wiley Capital Management LLC, owns 141,148 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $9.5 M.
As of the Q4 2025 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.03% of HOTCHKIS & WILEY's publicly disclosed stock portfolio, making it one of their key holdings.
HOTCHKIS & WILEY's peak holding in Halozyme Therapeutics, Inc. (HALO) was 141,148 shares, as reported at the end of Q4 2025.